Results 121 to 130 of about 2,655 (208)

Increased integration and synergy in EEG- and fNIRS-based data in migraine patients after a three-month treatment with galcanezumab: relations with long-term clinical outcome. [PDF]

Sci Rep
La Rocca M, Lacalamita A, Clemente L, Paparella G, Ammendola E, Amoroso N, Ladisa E, Monaco A, Stramaglia S, Bellotti R, de Tommaso M.   +10 more
europepmc   +1 more source

The Most Current and Effective Pharmaceutical Treatment Options for Chronic Migraines [PDF]

Chronic migraine (CM) is a debilitating condition that affects a significant portion of the population. Treatment for CM is a current area of research with new medications being developed. One of the latest mechanisms of action for treatment is targeting
Hall, Hannah, Riley, Sophia, Van Otterloo, Jill, Wright, Sierra   +3 more
core   +1 more source

Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis. [PDF]

Headache
Fernández-Bravo-Rodrigo J, Pascual-Morena C, Saz-Lara A, Martínez-García I, Lever-Megina CG, Patiño-Cardona S, Flor-García A, Cavero-Redondo I.   +7 more
europepmc   +1 more source

Safety and efficacy of calcitonin gene-related peptide antagonists for cluster headache: a systematic review and meta-analysis. [PDF]

BMC Neurol
Khanfar R, Radwan E, Hattab S.
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, in Healthy Chinese Participants. [PDF]

Clin Pharmacol Drug Dev
Wang J, Li N, He J, Zhang J, Wang L, Kielbasa W, Qian C, Zhang Y, Wang L.   +8 more
europepmc   +1 more source

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis. [PDF]

J Headache Pain
Romozzi M, Palermo M, Danno D, Katsuki M, Tosto F, Signorelli F, Vollono C, Matsumori Y, Calabresi P, Ornello R, Iannone LF.   +10 more
europepmc   +1 more source

Recent Trends in the Pharmacological Treatment of Chronic Migraine: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Sharma J, Soni R, Singh S.
europepmc   +1 more source

Botulinum Toxin Type A for the Prevention of Migraines: An Umbrella Review of Systematic Reviews. [PDF]

Toxins (Basel)
Chamani G, Jasim H, Minston A, Dias MF, Poluha RL, Gonçalves DAG, Christidis M, Al-Moraissi EA, Christidis N, De la Torre Canales G, Ernberg M.   +10 more
europepmc   +1 more source

Effect of Galcanezumab on PHQ-9 and GAD-7 in Patients with Migraine: A Real-world Study in Japan. [PDF]

Intern Med
Oshima K, Hattori Y, Ihara K, Watanabe N, Takemura R, Ishizuchi K, Takahashi N, Sekiguchi K, Nakahara J, Takizawa T.   +9 more
europepmc   +1 more source

Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgias. [PDF]

Headache
Vila-Pueyo M, Goadsby PJ, Johnson KW, Holland PR.   +3 more
europepmc   +1 more source